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Variability of Symmetric Dimethylarginine in Apparently
Healthy Dogs
M.A. Kopke, R.K. Burchell , C.G. Ruaux , S.E. Burton, N. Lopez-Villalobos, and A. Gal
Background: Symmetric dimethylarginine (SDMA) is a screening tool for early kidney dysfunction and monitoring treatment in cases of
chronic kidney disease (CKD). There are no current studies describing the suitability of this test for use with published population-
based reference intervals.
Hypothesis/Objectives: To determine the components of biological variability, the index of individuality (IOI), the critical
difference between sequential measurements (CD) and the number of measurements required to assess the homeostatic set point (HSP),
for both SDMA and serum creatinine (sCr), in apparently healthy dogs.
Animals: Twenty apparently healthy adult dogs owned by clients or staff at a veterinary teaching hospital.
Methods: Prospective, observational study. Blood was collected from each dog on 9 occasions, and SDMA and sCr were measured in
duplicate using commercially available assays.
Results: SDMA and sCr had intermediate and low IOI values of 0.87 and 0.28, respectively. The CD of SDMA and sCr, was 1.34 mg/dL
and 0.89 mmol/L, respectively. The sample numbers required for estimation of an individual’s HSP (with 90 and 95% CI) for SDMA
and sCr were 8 and 45, and 2 and 12 sequential measurements, respectively.
Conclusions and Clinical Importance: Based on our findings, in comparison to sCr, SDMA is better suited for use with population-
based reference intervals. False-negative test results could occur when comparing a single test result from an individual to such
intervals. Ideally CD should be used with sequential measurements.
Key words: Canine; Chronic kidney disease; Critical difference; Index of individuality; Serum creatinine; Symmetric
dimethylarginine.
S ymmetric dimethylarginine (SDMA) is a relatively newindirect biomarker of glomerular filtration rate (GFR),
and kidney function.1,2 It has several advantages over serum
creatinine (sCr) in detecting decreased GFR. SDMA detects
loss of renal function earlier and is less affected by extra-
renal factors such as age, sex, breed, and lean body mass.1–6
The use of SDMA has thus become more extensive, not
only in screening for early kidney dysfunction, but also as a
therapeutic monitoring tool in chronic kidney disease
(CKD).1,2 SDMA has been incorporated into the Interna-
tional Renal Interest Societya CKD Staging Guidelines on a
preliminary basis.
The clinical utility of a reference interval and the per-
formance of a screening test, are dependent on the total bio-
logical variability (TBV) of the test. The intraindividual
variability, interindividual variability, and analytical vari-
ability of the assay comprise the TBV.7–9 Determination of
the TBV of a biomarker establishes the limits of normality
and thus the inability to conclude abnormality, if the result
falls within the limits of the established reference interval
(Fig 1).10 Tests with high individuality possess low
intraindividual and high interindividual variability and may
not provide clinically useful information when interpreting
a single result from an individual, if that result happens to
fall within the reference interval. The index of individuality
(IOI) describes the relationship between the intraindividual
and interindividual variability for a given diagnostic test,
with IOI values classified as low (<0.6) or high (>1.4).7,9
The individual’s homeostatic set point (HSP) is derived
from the mean and confidence intervals (CI) of the test vari-
able with repeated measurements. Tests with a low IOI will
have the individual’s HSP spanning a small fraction of the
reference interval and are thus not well-suited for use in
population-based reference intervals.7,8 With such tests, it
becomes important to calculate the critical difference (CD)
which is the minimum change necessary between sequential
results for an individual to exceed the TBV of the test.7
Several studies have investigated the TBV and clinical util-
ity of various tests in veterinary medicine including; hemato-
logical variables,11 platelet function,12 hemostatic variables,13
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CVI intraindividual coefficient of variation
CVT total biological coefficient of variation
GFR glomerular filtration rate
HSP homeostatic set point
IOI index of individuality
IRIS international renal interest society
sCr serum creatinine
SDMA symmetric dimethylarginine
TBV total biological variability
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cardiac troponin I,14 N-terminal pro-brain natriuretic pep-
tide,14,15 serum cystatin C,16,17 C-reactive protein,18 specific
canine pancreatic lipase immunoreactivity,18 canine serum
cortisol concentration post-adrenocorticotropic hormone stim-
ulation,19 and canine serum thyrotropin concentration.20
Based on the current veterinary literature regarding
SDMA, we hypothesized that SDMA would have a lower
individuality than sCr because of less influence from extra-
renal factors. The aims of the study were to (1) determine
the IOI of SDMA and sCr, (2) estimate the CD for both tests,
and (3) estimate the number of samples required to deter-
mine the HSP for an individual dog, for both biomarkers.
We approached the study aims by obtaining serial measure-
ments of SDMA in apparently healthy dogs to determine the
components of TBV of SDMA. We also obtained serial
measurements of sCr in order to contrast SDMA with
creatinine.
Materials and Methods
Animals
Blood was collected from 20 adult dogs weighing over 10 kg that
were privately owned by clients or staff members at the Massey Univer-
sity Veterinary Teaching Hospital. The owners of the dogs considered
the dogs to be in good health and a veterinarian examined the dogs before
the commencement of the study. These dogs were fasted overnight and
had free access to water before and after the blood collection. Diets and
housing conditions differed depending on owner preference. Table 1
describes the characteristics of the cohort of dogs included in this study.
Study Design
The Massey University Animal Ethics Committee approved the
study (protocol #16/102).
The prospective analysis was performed on 20 apparently healthy
dogs. To minimize pre-analytical variation, both sample collection and
processing were standardized. A total of 9 separate blood samples were
collected between 0800 and 1000 hours from each dog after an overnight
fast (8 hours). Each 2 mL sample was obtained after gentle manual
restraint (with the dog in a sitting position) and drawn via jugular veni-
puncture using a 20 G needle and a 3 mL syringe.b The blood samples
were collected on Days 1, 3, 5, 12, 19, 26, 40, 54, and 68. After collec-
tion, blood was transferred into serum tubes.c Samples were allowed to
clot at room temperature, were centrifugedd at 3,000 g for 15 minutes,
and the serum was then decanted and stored in sealed aliquots at 2808C
until analysis. At the end of the study period, the samples were submitted
to a reference diagnostic laboratorye for analysis. SDMA3,[f] and serum
creatinine (sCr)g were measured for each sample, in duplicate, with com-
mercially available, previously validated assays. Both assays were per-
formed according to the manufacturers’ recommendations. The lower
and upper limits of quantification of the 2 assays were 0–100 mg/dL and
4–4420 mmol/L for SDMAf and sCr,g respectively.
Statistical Analysis
We performed all statistical analyses in R 3.3.3.21 We used the lm()
function in the lme4 package22 to perform analyses of variances of the
Fig 1. Graphic representation of 2 hypothetical diagnostic tests
explaining the concepts of high and low IOI, respectively. Tests with
high individuality have a low IOI value and vice versa. Test A dem-
onstrates high IOI because of high intraindividual variability and low
interindividual variability. With a high IOI, the values span a large
proportion of the population-based reference interval and thus is suita-
ble for a single value to be interpreted using such an interval. Test B
demonstrates a low IOI, with low intraindividual variability and high
interindividual variability. With a low IOI, the values only span a
small proportion of the population-based reference interval and thus
such tests are not suitable for interpretation of a single value for an
individual, using such an interval. In the case of test B, a normal test
result will not necessarily accurately identify deviation from normal
for a specific individual. IOI, index of individuality; gray solid lines,
upper and lower reference limits of the population-based reference
range; vertical line with a dot in the center, each dogs’ test mean and
confidence interval for the mean.
Table 1. Dog demographics.
Variable Value
Sample size (n) 20
Agea (mean6 SD) 766 36.9
Weightb (median and range) 26.25 (15–46)
BCSc (median and range) 5 (3–7)
Sex
Male entire 4
Female entire 3
Male neutered 6
Female spayed 7
Breed
Huntaway (New Zealand Sheepdog) 6
Collie 6
Greyhound 3
Harrier Hound, Jack Russell Terrier, Labrador
Retriever, Maremma Sheepdog, Huntaway/
Labrador Retriever crossbreed
1 each
BCS, body condition score; SD, standard deviation.
aAge in months.
bBody weight in kg.
cBCS in a scale of 1–9.
737IOI of SDMA
dependent variables “SDMA” and “creatinine” with a linear model that
included the random effects of “dog,” “sample,” and “duplicates.”7 Vis-
ual inspection of residual plots did not reveal any obvious deviations
from homoscedasticity or normality. The CD was calculated by the for-
mula, CD5 1.96[2 (VarI1VarA)]
1/2, where VarG, VarI, and VarA are
the interindividual, intraindividual and analytical variance components
derived from the expectation of the mean squares as outlined by Fraser
and Harris.7 The coefficients of variation (CV) for intraindividual
(CVI), interindividual (CVG), and the analytical (CVA) components of
the total variance were calculated by dividing the SD of each by the
mean. The IOI was calculated as (CV2I 1CV
2
A)
1/2/CVG. The number of
specimens that should be assayed to be X% confident of achieving an
estimate of the HSP within D% of an individual dog was calculated
from the formula n 5 ZX
2(CV2I 1CV
2
A)/D
2, where ZX is the percentile
of the standard normal distribution and D is the desired percentage
closeness to the HSP (ZX5 1.645 for X5 90% and D5 10%; ZX5 1.96
for X5 95% and D5 5%).19 We used the outliers package23 cochran.t-
est() function to test if any of the dogs was significantly influencing the
variance from the other dogs and the BlandAltmanLeh package24 blan-
d.altman.plot() function to generate the Bland–Altman plot. We used
the lmerTest package22,25 lmer() function to perform a regression analy-
sis for repeated measures, to evaluate the relationship between the fixed
effect factor “day of sampling” and the dependent variables “SDMA”
and “creatinine”; a random intercept was fitted for each dog. A P val-
ue< 0.05 indicated the presence of statistical significance.
Results
The means and 90% confidence intervals (CI) for SDMA
and serum creatinine (sCr) of 20 apparently healthy dogs
and the group mean with respect to the reference laboratory
population-based reference interval are presented in
Figures 2 and 3, respectively. The results of the mean, coef-
ficients of variation (CV) for CVG, CVI, CVA, the variances
(Var) for VarG, VarI, VarA, the critical difference (CD), CD
%mean, and IOI for both SDMA and sCr, and the numbers
of measurements required to assess the HSP for either test
with CI of 90 and 95%, are summarized in Table 2. The
CVG, CVI and CVA for SDMA were 19.5, 14, and 9.5%,
respectively. In comparison the CVG, CVI, and CVA for sCr
were 30.1, 8.32, and 2%, respectively. Furthermore, the 90
and 95% CI for the individual’s HSP for SDMA required 8
and 45 sequential measurements, respectively, in compari-
son to 2 and 12 sequential measurements for sCr. Finally,
we calculated IOI values of 0.87 and 0.28 for SDMA and
sCr, respectively. The mixed-effect regression analysis indi-
cated that there was a significant effect of the sampling day
on SDMA and sCr. Relative to Day 1, SDMA (mean, SE)
on Days 12 and 26 was lower by 21.526 0.46 (P5 0.001)
mg/dL and 21.436 0.46 (P5 0.002) mg/dL, respectively.
The effect of time on sCr was opposite to that of SDMA.
Relative to Day 1, sCr (mean, SE) on Day 40 was greater by
3.956 1.8 (P5 0.03) mmol/L. There was a significant
(P< 0.001) moderate to high correlation (r5 0.7) between
SDMA and sCr (Fig 4). The Bland–Altman plot (Fig 5)
indicated a proportional bias for sCr relative to SDMA; that
is, the difference between the 2 measurements becomes
greater at higher values for the 2 tests.
Discussion
The purpose of our study was to estimate the IOI for
SDMA and sCr to determine their suitability for use with a
population-based reference interval. Our study demon-
strated intermediate and low IOI values (ie, high individual-
ity) of 0.87 and 0.28 for SDMA and sCr, respectively.
According to our results, in comparison to sCr, SDMA is
better suited for use in population-based reference intervals.
A subject’s HSP for a laboratory test is defined as the
mean value from repeated measurements for that individual,
bounded by the confidence interval for the mean.7 In
healthy individuals, the HSP should almost always exist
Fig 2. Serum symmetric dimethylarginine (SDMA) concentrations in 20 apparently healthy dogs sampled 9 times at varying intervals. The box
and whiskers represent the median and 1.53 interquartile ranges for SDMA from 9 measurements. The red dot with error bars represent the mean
and 90% CI (ie, the homeostatic set point of the individual). The gray dashed lines represent the population-based reference intervals 0–14 mg/dL.
The gray dotted line represents the group’s mean. Gray empty circles represent outlying data.
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within the population-based reference interval for the test.
The IOI measures the degree of individuality of a laboratory
test, with tests possessing high individuality demonstrating
a low IOI value. In the case of a laboratory test with a high
individuality, the individual’s HSP spans a small fraction of
the population-based reference interval. Therefore, a test
with high individuality has the limitation that if its value
falls within the population-based reference interval, but out-
side of the individual’s HSP, it could be falsely interpreted
as normal (ie, false negative).
The general recommendation for assays with a low to
intermediate IOI is to use the critical difference (CD)
between sequential measurements rather than to rely on
population-based reference intervals. In that situation, a dif-
ference between 2 measurements that is equal to or smaller
than the CD could be the result of random variation rather
than a true biological change in the individuals test variable.
In this study we found that the CD’s of SDMA and sCr,
were 1.34 mg/dL and 0.89 mmol/L, respectively. Given that
the CD of sCr is 0.93% of the group mean, a slight differ-
ence between sequential measurements >0.93% would be
considered abnormal. The International Renal Interest Soci-
ety (IRIS) staging protocola suggests that the assessment of
sCr should take place at least twice in the stable patient to
overcome the biological variability. According to the results
of our study as depicted graphically in Figure 3, none of our
dogs were stable because they all had at least 2 measure-
ments that were above the calculated CD. Hence, the IRIS
algorithm for IRIS Stage 1 would be more accurate if the
HSP was calculated. According to our results, 12 measure-
ments would be required to find the HSP with 95%
Table 2. The results of the mean, CVI, CVG, CVA, VarI,
VarG, VarA, CD, CD %mean, and IOI for SDMA and sCr,
and the numbers of measurements required to assess the
HSP with 90 and 95% CI, for SDMA and sCr.
Parameter SDMA (mg/dL) sCr (mmol/L)
Mean 12.7 96.1
VarG 6.1 836
VarI 3.2 64
VarA 1.5 3.7
CVG 19.5 30.1
CVI 14 8.3
CVA 9.5 2
CD 1.34 0.9
CD %mean 10.5 0.93
IOI 0.87 0.28
CI 90% 8 2
CI 95% 45 12
VarG, interindividual variance; VarI, intraindividual variance; VarA,
analytical variance; CVG, interindividual coefficient of variation; CVI,
intraindividual coefficient of variation; CVA, analytical coefficient of
variation; CD, critical difference; IOI, index of individuality; CI, con-
fidence interval.
Fig 4. Scatter plot of symmetric dimethylarginine concentrations
(mg/dL) against serum creatinine (mmol/L) from 20 apparently healthy
dogs, showing a positive correlation between the 2 variables
(R25 0.49; P< 0.001).
Fig 3. Serum creatinine (sCr) concentrations in 20 apparently healthy dogs sampled 9 times at varying intervals. The box and whiskers represent
the median and 1.53 interquartile ranges for sCr from 9 measurements. The red dot with error bars represent the mean and 90% CI (ie, the
homeostatic set point of the individual). The gray dashed lines represent the population-based reference intervals 53–123 mmol/L. The gray dotted
line represents the group’s mean. Gray empty circles represent outlying data.
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confidence interval. Future studies on dogs with IRIS Stages
2, 3, and 4 will determine if the number of measurements
needed to establish the HSP is similar or different from our
results. Opinions vary as to whether such studies should be
conducted in healthy individuals or those with stable dis-
ease. In the human literature, no significant difference has
been documented in studies aimed at evaluating the compo-
nents of biological variability when performed in the
healthy versus the stable disease state.10,26,27
Our study indicates that, from the perspective of biologi-
cal and analytical variability, SDMA is superior to sCR as a
biomarker for detecting early kidney dysfunction. As shown
in Figures 2 and 3, SDMA had less interindividual variabil-
ity. The decreased interindividual variability and increased
CD of SDMA relative to sCr decreases the probability that a
given SDMA test result would be outside the individual’s
HSP for SDMA. An explanation for the increased interindi-
vidual variability with sCr might be the variances in age and
lean body mass across our study, shown in Table 2. Age and
lean body mass influence sCr concentration but do not influ-
ence SDMA concentration.4
When assessing the biological variance of several bio-
markers of GFR in healthy dogs, an intermediate IOI value
of 0.8 for sCr was estimated in a previous study,16 in con-
trast to the low IOI value of 0.28 in our study. This same
study16 found marked variation between their findings and
yet another study estimated an IOI value of 1.15.26 A poten-
tial reason for such marked difference between both previ-
ous studies and ours would be that short-term studies tend to
yield higher individuality when compared to long-term stud-
ies.7,16,28 Factors such as storage time, temperature and sam-
ple type could also influence the degree of individuality
during the storage period.29
In this study, the calculated SDMA mean was 12.7 mg/dL
(Table 2). The SDMA mean was in the top quarter of the
population-based reference interval (Fig 2). This could argue
for revision of the current published reference interval. The
reference laboratory utilized in this study made use of pub-
lished population-based reference intervals established for
use in healthy dogs older than 1 year of age.h With adoption
of such intervals there is the risk that in some cases the refer-
ence interval may not be appropriate for either the method of
measurement or alternatively the population of animals to
which it is applied. To avoid such problems, a transference
study should be performed to determine whether the
population-based reference interval is suitable for the popula-
tion being evaluated.9 A transference study is an extended
correlation determining the amount of bias between the estab-
lished population-based reference interval of the first popula-
tion and the target population. The published reference
interval is then adapted to fit the target population, using the
amount of bias determined. The advantage of a transference
study is that a smaller number of subjects is required for such
an analysis compared to the number that is required to deter-
mine a new population-based reference interval.9
A previous study1 documented a moderately high correla-
tion (r5 0.84) between SDMA and sCr. In agreement with
that study, our study demonstrated a mildly lower correla-
tion between SDMA and sCr concentrations (r5 0.7),
depicted graphically in Figure 4. Despite the moderate to
high correlation between sCr and SDMA, the Bland–Altman
plot in Figure 5 indicates a proportional bias for sCr relative
to SDMA. This proportional bias can be attributed to pro-
gressive increase in sCr values or a progressive decrease in
SDMA values. The proximal convoluted tubules are respon-
sible for a small component of active secretion of creatinine.
The measured sCr is the sum of this small component and
the large component of glomerular filtration. In the early
stages of loss of renal function there is a sharp exponential
drop in GFR. The population-based reference interval for
sCr fails to show the early fall in GFR as sCr values fall
within the reference interval. In contrast to sCr, SDMA is
freely filtered without a component of tubular active excre-
tion. Hence, we suspect that this is causing a proportional
bias of sCr relative to SDMA. Alternatively, if SDMA and
sCR have non-linear, differing, relationship to GFR, it is not
unexpected that differences between the 2 measurements
will become greater at higher values for the 2 tests.
We found that time of sampling had a significant effect
on both SDMA and sCr albeit in an opposite direction. In
other words, SDMA and sCr concentrations were signifi-
cantly lower and higher, respectively, from Day 1 on vari-
ous days. A dietary effect and an environmental effect such
as weather are unlikely because the effect of time on SDMA
and sCr was opposite and dogs were not sampled simultane-
ously to each other to experience the same weather condi-
tions. Altering the diet was found to affect SDMA after 3
and 6 months.4 However, the dogs in this study were on dif-
ferent diets and as mentioned above, we sampled them
sequentially and not simultaneously. The pattern of days
affected seems random, and highlights the significant effect
that biological variability may have.
Several limitations were identified with this study, the
first being slight breed overrepresentation, with the majority
of animals enrolled being Huntaway/Huntaway cross (New
Zealand sheepdog) and collies. Although this large percent-
age of working dogs accurately reflects the dog population
in New Zealand, this is not globally representative. In addi-
tion to this, apart from 1 Jack Russell terrier, no small breed
Fig 5. Bland–Altman plot demonstrating a progressive proportional
bias between the 2 tests. As the renal function declines there is a pro-
portional increase in serum creatinine relative to symmetric dimethy-
larginine. The middle dashed line represents the mean difference
between SDMA and sCr. The upper and lower dashed lines are 2 SD
above and below the mean difference between SDMA and sCr (middle
dashed line).
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dogs were enrolled in the study. That being said, extra-renal
factors such as breed and lean body mass have not been
shown to affect SDMA concentrations in dogs.4,6 Another
potential limitation of our study was the use of a competi-
tive ELISA assayf for SDMA measurement, rather than
mass spectrometry. The latter is considered the gold stand-
ard for SDMA quantification with better selectivity and sen-
sitivity, however, the above assay has been shown to have a
high correlation with mass spectrometry.3 The use of a pub-
lished population-based reference interval in this study,
without a transference study having been performed to
ascertain its suitability for the population being sampled,
was another limitation of our study. Assessment of the bio-
logical variability of SDMA in apparently healthy animals
without information on their urine specific gravity, might be
another potential limitation if an inference on azotemic dogs
is sought. However, as mentioned previously, no significant
difference in biological variability has been documented in
similar studies performed in healthy versus stable disease
state individuals in the human literature.10,26,27
In conclusion, both SDMA and sCr were found to have
moderate to high individuality with a intermediate to low
IOI that could account for significant false-negative test
results in dogs with early kidney dysfunction; more so with
sCr than SDMA. Hence, according to our results, we high-
light the limitation of both tests as screening tests when
comparing a single value for an individual to published
population-based reference intervals. This emphasizes the
importance of serial monitoring, when trying to diagnose
early kidney dysfunction and the need for application of CD.
We found that for SDMA, CD should be >1.34 mg/dL to
ensure that the difference, whether an increase or decrease
between sequential measurements, is not because of biologi-
cal variability. Future studies should involve further investi-
gation into sCr and SDMA in the diseased state, according
to IRIS CKD Staging Guidelines, to assess the potential use
of the CD for monitoring changes in renal function.
Footnotes
a IRIS Staging of CKD. International Renal Interest Society website.
Iris-kidney.com/guidelines/staging.html. 2015, VC 2016 International
Renal Interest Society (IRIS)
b BD PrecisionGlide Needle 20G 1TW and 3 mL Luer-Lok Tip
Syringes, Singapore
c BD Vacutainer Red Top Tubes, Singapore
d Heraeus Multifuge X3, Thermo Fisher Scientific, Waltham, MA
e IDEXX Laboratories, Inc, Palmerston North, New Zealand
f Patch D, Obare E, Xie H. High throughput immunoassay that corre-
lates to gold standard liquid chromatography mass spectrometry
(LC-MS) assay for the chronic kidney disease (CKD) marker sym-
metric dimethylarginine (SDMA). J Vet Intern Med 2015;29:1216
(abstract)
g Beckman Coulter AU CREA Creatinine (Enzymatic), Australia
(http://www.accrediweb.fr/Biochimie/Gamme_AU/Notices_Utilisa-
tion/Metabolites/CREATININE_ENZYMATIQUE_BLOSR6x204_
07_FR.pdf)
h Rentko V, Nabity MB, Yerramilli M, et al. Determination of serum
symmetric dimethylarginine reference limit in clinically healthy
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